Sana to Up Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases

 Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells

Modified strategy extends expected cash runway into 2026 with potential for multiple data readouts in 2024 and 2025

The company will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs. Sana will increase its investment in its type 1 diabetes program with the cash savings from these changes.

https://www.globenewswire.com/news-release/2024/11/04/2974495/0/en/Sana-Biotechnology-Announces-Increased-Focus-on-Type-1-Diabetes-and-B-cell-Mediated-Autoimmune-Diseases-with-the-Potential-to-Deliver-Clinical-Proof-of-Concept-Data-Across-Multiple.html